Melinda B. Chu

Evaluation of the Definitions of “High-Risk” Cutaneous Squamous Cell Carcinoma Using the American Joint Committee on Cancer Staging Criteria and National Comprehensive Cancer Network Guidelines

Melinda B. Chu, Jordan B. Slutsky, Maulik Dhandha et al. · Journal of Skin Cancer · 2014 · 47 citations · Full text

Surgical Oncology, American Joint Committee, Cancer Management +20

Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial

Scott W. Fosko, Melinda B. Chu, Eric S. Armbrecht et al. · Journal of the American Academy of Dermatology · 2019 · 24 citations

Tumor Response, Tumor Biology, Medicine +10

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

Melinda B. Chu, Mark Fesler, Eric S. Armbrecht et al. · Chemotherapy Research and Practice · 2013 · 20 citations · Full text

Surgical Oncology, Immunology, Brain Lesion +17

Ulcerated Infantile Hemangioma: Novel Treatment with Topical Brimonidine‐Timolol

Brandon T. Beal, Melinda B. Chu, Elaine C. Siegfried · Pediatric Dermatology · 2014 · 15 citations

Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing

Melinda B. Chu, Garrett Searcy, Elaine C. Siegfried · BMJ Case Reports · 2013 · 13 citations · Full text

Brimonidine 0.2, Ocular Disease, Ophthalmology +14